Loading
Life sciences · Journal article
International Journal of Drug Delivery Technology · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Nonalcoholic fatty liver disease (NAFLD), a term increasingly superseded by metabolic dysfunction-associated steatotic liver disease (MASLD) in contemporary nomenclature, is among the most common chronic liver diseases worldwide and is closely associated with insulin resistance, obesity, and metabolic syndrome.It is often asymptomatic in its early, potentially reversible stages and is linked to energy excess, physical inactivity, and elevated cardiometabolic risk; management therefore depends chiefly on sustained lifestyle change.Classical Ayurveda describes over-nutritional states as Santarpanajanya Vikara and proposes the reciprocal strategy of Apatarpana, of which Langhana (lightening therapy) is a principal measure.Among its varieties, Upavasa (fasting) is the most direct and practicable.This narrative integrative review relates classical descriptions of Langhana and Upavasa to contemporary NAFLD pathophysiology and clinical evidence on fasting.It proposes a structured Upavasa-day protocol comprising preparation, graded restriction, and planned breaking of the fast.This protocol may be integrated into established fasting regimens, including 5:2 calorie restriction, alternate-day fasting, and timerestricted eating.Randomised trials suggest that intermittent-fasting approaches can reduce hepatic steatosis, transaminase concentrations, and selected cardiometabolic markers; however, much of the benefit appears to be mediated by energy deficit and adherence rather than meal timing alone, and a benefit for fibrosis remains unproven.The proposed protocol is a culturally grounded adjunct for selected adults without advanced fibrosis or cirrhosis and is offered for prospective clinical evaluation rather than as a replacement for guideline-based care.